Filing Details

Accession Number:
0001694665-23-000169
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-03 16:12:23
Reporting Period:
2023-11-01
Accepted Time:
2023-11-03 16:12:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1694665 Evelo Biosciences Inc. EVLO Pharmaceutical Preparations (2834) 465594527
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1738885 Mark Bodmer C/O Evelo Biosciences, Inc.
One Kendall Square, 600/700, Suite 7-201
Cambridge MA 02139
Cso, President Of R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-01 12,500 $0.00 29,124 No 4 M Direct
Common Stock Disposition 2023-11-02 6,854 $0.33 22,270 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-11-01 12,500 $0.00 12,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,000 No 4 M Direct
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
  2. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.31 to $0.33, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
  4. The RSUs vest in three (3) substantially equal installments on each of November 1, 2023, February 1, 2024 and May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These RSUs have no expiration date.